MacKinnon Named CEO at Saranas
6 March 2023 - - US-based medical device company Saranas Inc has hired seasoned medtech executive, Mike MacKinnon, as chief executive officer, the company said.

He joins the company to accelerate commercialization of its Early Bird Bleed Monitoring System the first and only system FDA-approved bleed detection system for endovascular procedures.

It is designed to detect bleeds early, enabling physicians to address and mitigate the risk immediately, reducing costly complications and improving the patient experience.

Mike brings 25 years of executive leadership experience and most recently was a Partner and president of Madison Ventures +, a boutique Private Equity firm located in Greenwood Village, CO.

Before joining Madison Ventures +, he was the CEO of Zidan Medical, an early-stage company focused on endobronchial ablation for early-stage lung cancer.

Prior to this, he served as the CEO of ROX Medical, a privately held medical device company that pioneered an innovative interventional vascular therapy for uncontrolled hypertension.

Before his most recent roles, Mike spent 4 years as vice president, Head of Sales, for Philips North America's Image Guided Technologies division, where he was instrumental in the development and growth of the company's interventional devices business.

Mike also played a key role with M&A during his time at Philips, where he led the commercial due diligence for the acquisition of Spectranetics for more than USD 2bn in 2017 and ultimately integrated a combined 500-person sales team.

He joined Philips after the company's acquisition of Volcano Corp., where he served as the general manager of Phoenix Atherectomy division and Peripheral Sales Leader. He originally joined Volcano as part of the acquisition of AtheroMed in June 2014, which he led as CEO.

The Early Bird Bleed Monitoring System includes a bleed detection array with integrated electrodes in a fully functional vascular access sheath. It is designed to measure changes in bioimpedance to detect and monitor bleeding from vessel injury.

Visual and audible indicators on the Early Bird notify the clinician of the onset and progression of bleeding events.

In the FIH clinical study, bleed detection with the Early Bird was compared with a CT scan, the gold standard, and level of agreement was nearly perfect with 100% sensitivity.

Approximately one in every five patients will experience a bleeding complication during large-bore endovascular procedures including transcatheter aortic valve replacement, endovascular aneurysm repair, and percutaneous mechanical circulatory support 2.

The average cost of a single bleeding complication incident across these large-bore procedures is approximately USD 18,000 with an estimated USD 729m cost on the healthcare system.

Saranas, Inc. is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications.

The company's patented Early Bird Bleed Monitoring System for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes, and lowering healthcare costs.